Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01951586
• Other study ID #: 20120249
• Secondary ID: 2013-001662-42
• Status: Completed
• Phase: Phase 2
• Start date: December 31, 2013
• Est. completion date: November 28, 2017

Study information

• Verified date: October 2021
• Source: Amgen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.

Description:

This is a global randomized double-blind placebo-controlled study in patients with Stage IV untreated non-small cell lung cancer (NSCLC) with or without bone metastasis. Eligible participants are to receive 4 to 6 cycles of a standard of care platinum-doublet chemotherapy regimen. Participants will be randomized in a 2:1 ratio to receive denosumab or matching placebo with the first investigational product dose coinciding with participant's first cycle of chemotherapy and continuing until the primary analysis, unacceptable toxicity, withdrawal of consent, death, or lost to follow-up. Participants who discontinued the investigational product early (ie, before primary analysis) were followed for disease status and survival. The primary analysis took place when 149 events of death had been reported. All participants were followed for 2 years after the last dose of blinded investigational product.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 226
• Est. completion date: November 28, 2017
• Est. primary completion date: July 29, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed stage IV non-small cell lung carcinoma (NSCLC), according to 7th Tumor/Node/Metastasis (TNM) classification (cytological specimens obtained by bronchial washing or brushing, or fine-needle aspiration are acceptable)
• Subject has available and has provided consent to release to the sponsor (or designee) a tumor block with confirmed tumor content (or approximately 20 unstained charged slides [a minimum of 7 slides is mandatory]) and the corresponding pathology report
• Planned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin
• For subjects to receive pemetrexed, planned to receive vitamin B12 and folate per pemetrexed approved labeling
• Radiographically evaluable (measurable or non-measurable) disease (according to modified Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria
• Other inclusion criteria may apply

Exclusion Criteria:

• Known presence of documented sensitizing epidermal growth factor receptor (EGFR) activating mutation or echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocation (screening following local standards, but strongly encouraged in non-squamous histology)
• Known brain metastases (systematic screening of patients not mandatory)
• Any prior systemic therapy (before randomization) for the treatment of NSCLC (including chemoradiation), except if for non-metastatic disease and was completed at least 6 months prior to randomization
• Planned to receive bevacizumab
• Significant dental/oral disease, including prior history or current evidence of

osteonecrosis/ osteomyelitis of the jaw, or with the following:

• Active dental or jaw condition which requires oral surgery
• Non-healed dental/oral surgery
• Planned invasive dental procedures for the course of the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-Small Cell Lung Cancer

Intervention

Drug:
• Denosumab
Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
• Zoledronic acid
Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
• Placebo to Denosumab
Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
• Standard Chemotherapy
Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
• Placebo to Zoledronic Acid
Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.

Locations

Country	Name	City	State
Australia	Research Site	Adelaide	South Australia
Australia	Research Site	Footscray	Victoria
Australia	Research Site	Kogarah	New South Wales
Australia	Research Site	Parkville	Victoria
Australia	Research Site	Wahroonga	New South Wales
Australia	Research Site	Wodonga	Victoria
Canada	Research Site	Edmonton	Alberta
Canada	Research Site	Kitchener	Ontario
Canada	Research Site	Montreal	Quebec
Canada	Research Site	Saint John	New Brunswick
Canada	Research Site	Sudbury	Ontario
Canada	Research Site	Toronto	Ontario
Canada	Research Site	Toronto	Ontario
Czechia	Research Site	Chomutov
Czechia	Research Site	Ostrava-Poruba
Czechia	Research Site	Pardubice
Czechia	Research Site	Praha 8
Czechia	Research Site	Usti nad Labem
France	Research Site	Caen Cedex 5
France	Research Site	Dijon cedex
France	Research Site	Nantes Cedex 2
France	Research Site	Paris Cedex 10
France	Research Site	Paris Cedex 14
France	Research Site	Paris Cedex 20
France	Research Site	Pessac Cedex
France	Research Site	Reims Cedex
France	Research Site	Saint Quentin
France	Research Site	Tours Cedex 9
Germany	Research Site	Berlin
Germany	Research Site	Grosshansdorf
Germany	Research Site	Köln-Merheim
Germany	Research Site	Ulm
Greece	Research Site	Athens
Greece	Research Site	Athens
Greece	Research Site	Heraklion
Greece	Research Site	Patra
Greece	Research Site	Thessaloniki
Greece	Research Site	Thessaloniki
Italy	Research Site	Monza (MB)
Italy	Research Site	Orbassano (TO)
Italy	Research Site	Pavia
Italy	Research Site	Roma
Italy	Research Site	Saronno VA
Netherlands	Research Site	's Hertogenbosch
Netherlands	Research Site	Arnhem
Netherlands	Research Site	Harderwijk
Netherlands	Research Site	Tilburg
Netherlands	Research Site	Zutphen
United Kingdom	Research Site	Bristol
United Kingdom	Research Site	Exeter
United Kingdom	Research Site	Glasgow
United Kingdom	Research Site	Guildford
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	Plymouth
United Kingdom	Research Site	Preston
United States	Research Site	Alexandria	Louisiana
United States	Research Site	Anaheim	California
United States	Research Site	Bismarck	North Dakota
United States	Research Site	Brewer	Maine
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Detroit	Michigan
United States	Research Site	Durham	North Carolina
United States	Research Site	East Setauket	New York
United States	Research Site	Fairhaven	Massachusetts
United States	Research Site	Farmington	Connecticut
United States	Research Site	Goodyear	Arizona
United States	Research Site	Hickory	North Carolina
United States	Research Site	Long Beach	California
United States	Research Site	Los Angeles	California
United States	Research Site	Los Angeles	California
United States	Research Site	Nashville	Tennessee
United States	Research Site	Westminster	Maryland
United States	Research Site	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Amgen

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Czechia,  France,  Germany,  Greece,  Italy,  Netherlands,  United Kingdom, 

References & Publications (1)

Peters S, Danson S, Ejedepang D, Dafni U, Hasan B, Radcliffe HS, Bustin F, Crequit J, Coate L, Guillot M, Surmont V, Rauch D, Rudzki J, O'Mahony D, Barneto Aranda I, Scherz A, Tsourti Z, Roschitzki-Voser H, Pochesci A, Demonty G, Stahel RA, O'Brien M. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer. 2021 Nov;161:76-85. doi: 10.1016/j.lungcan.2021.09.002. Epub 2021 Sep 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	Overall survival was calculated as the time from the date of randomization to the date of death from any cause. Participants last known to be alive were censored at the last contact date.	From randomization until the end of study; median time on study was 9.64 months.
Secondary	Correlation of Tumor Tissue RANK Expression With Overall Survival	To assess whether the treatment effect on overall survival was correlated with receptor activator of nuclear factor (NF)-?B (RANK) protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity.; The correlation between RANK expression level and OS was evaluated using a Cox proportional hazard models that included RANK expression level stratified by the randomization stratification factors in the corresponding treatment group.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Correlation of Tumor Tissue RANK Ligand Expression With Overall Survival	To assess whether the treatment effect on overall survival was correlated with RANK ligand (RANKL) protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity.; The correlation between RANKL expression level and OS was evaluated using a Cox proportional hazard models that included RANKL expression level stratified by the randomization stratification factors in the corresponding treatment group.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Objective Response Rate	Objective response rate was defined as the percentage of participants with a complete response (CR) or partial response (PR) based on modified RECIST 1.1 achieved over the study duration.; CR: Disappearance of all target and non target lesions, normalization of tumor marker levels and no new lesions.; PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, disappearance of target lesions with persistence of one or more non-target lesions and/or maintenance of tumor marker levels above normal limits and no new lesions.; Participants who underwent surgical resection while on study were not evaluated for response after the surgery. Participants who did not meet the criteria for an objective response by the analysis cutoff date were considered non-responders.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Correlation of Tumor Tissue RANK Expression With Objective Response Rate	To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANK protein expression in tumor cells, RANK expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm, membrane, and total was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity.; The correlation between RANK expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANK expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Correlation of Tumor Tissue RANKL Expression With Objective Response Rate	To assess whether the treatment effect on objective response rate (ORR) based on RECIST 1.1 was correlated with RANKL protein expression in tumor cells, RANKL expression in archival tumor samples was measured using immunohistochemistry. The intensity of stain in the cytoplasm was categorized as 0 (negative), 1+ (weak), 2+ (moderate) or 3+ (strong); All intensity is the sum of levels +1, +2 and +3. In addition, an H-score was calculated using the following formula: H-score=(percentage of cells of weak×1)+(percentage of cells of moderate×2)+(percentage of cells of strong×3). The maximum H-score was 300, corresponding to 100% of cells with strong intensity.; The correlation between RANKL expression level and ORR was evaluated within each treatment group using a logistical regression model that included RANKL expression value as an independent variable and stratified by the randomization stratification factors. The odds ratio and 95% confidence interval are reported.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Clinical Benefit Rate	Clinical benefit rate was defined as the percentage of participants with an objective response (CR or PR) or stable disease (SD) or better for at least 16 weeks achieved over the study duration. If a participant underwent surgical resection while on study, the participant was not evaluated for response after the surgery. Participants who did not meet the criteria for clinical benefit by the analysis cutoff date were considered as non-responders.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Progression-free Survival (PFS)	Progression-free survival was defined as the time from randomization to the first observed disease progression per modified RECIST 1.1 criteria or death from any cause. Participants last known to be alive who did not experience disease progression were censored at their last imaging assessment date, last contact date if they were in the survival follow up phase, end of the study date, or the primary analysis cut-off date, whichever was first. If a participant underwent surgical resection while on study, the participant was censored at the last evaluable imaging assessment prior to the surgery.	From randomization until the data cut-off date of 29 July 2016; median time on study was 9.64 months.
Secondary	Serum Denosumab Trough Levels in Participants Who Received Q3W Dosing	Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.	Prior to dosing at day 8 and weeks 3, 6, 9, 12, 15, 18, 21 and 24.
Secondary	Serum Denosumab Trough Levels in Participants Who Received Q4W Dosing	Serum samples were analyzed for denosumab using enzyme-linked immunosorbent assay (ELISA) following a validated procedure. The lower limit of quantification for the assay was 20 ng/mL.	Prior to dosing at day 8 and weeks 4, 8, 12, 16, 20 and 24
Secondary	Number of Participants With Treatment-emergent Adverse Events	An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment.; A serious adverse event is defined as an AE that meets at least 1 of the following criteria; fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event Treatment-related AEs include only TEAEs for which the investigator indicated there was a reasonable possibility they may have been caused by study drug.; Fatal adverse events include only deaths reported on the Adverse Event Case Report Form.	From first dose of study drug to the end of study date; the median (min, max) duration was 10.0 (0.2, 41.4) and 9.4 (0.2, 42.9) months for Placebo and Denosumab respectively.

External Links

•   AmgenTrials clinical trials website